Endo to pay $25M for nasal testosterone replacement therapy
Endo International made a bigger push into the testosterone replacement therapy market Monday by agreeing to acquire the rights to Natesto for $25 million.
Natesto is the only testosterone nasal gel approved by the Food and Drug Administration as a replacement therapy for adult males with hypogonadism.
Many testosterone gel replacement therapies are delivered through the skin in a patch or gel formulation. The condition is also treated with injectable medicines or drugs taken orally. Natesto is…
Source: bizjournals.com Health Care:Hospitals headlines - Category: Hospital Management Authors: John George Source Type: news
More News: AndroGel | Food and Drug Administration (FDA) | Health | Health Management | Hospital Management | Hospitals | Low Testosterone | Skin